

# Tomasz Kubiowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3773340/publications.pdf>

Version: 2024-02-01

4  
papers

27  
citations

2682572

2  
h-index

2272923

4  
g-index

4  
all docs

4  
docs citations

4  
times ranked

44  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	2.2	5
2	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	3.7	2
3	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
4	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	1.2	14